Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceuticals.

Rapid, large-scale manufacture of medical countermeasures can be uniquely met by the plant-made-pharmaceutical platform technology. As a participant in the Defense Advanced Research Projects Agency (DARPA) Blue Angel project, the Caliber Biotherapeutics facility was designed, constructed, commissioned and released a therapeutic target (H1N1 influenza subunit vaccine) in <18 months from groundbreaking. As of 2015, this facility was one of the world's largest plant-based manufacturing facilities, with the capacity to process over 3500 kg of plant biomass per week in an automated multilevel growing environment using proprietary LED lighting. The facility can commission additional plant grow rooms that are already built to double this capacity. In addition to the commercial-scale manufacturing facility, a pilot production facility was designed based on the large-scale manufacturing specifications as a way to integrate product development and technology transfer. The primary research, development and manufacturing system employs vacuum-infiltrated Nicotiana benthamiana plants grown in a fully contained, hydroponic system for transient expression of recombinant proteins. This expression platform has been linked to a downstream process system, analytical characterization, and assessment of biological activity. This integrated approach has demonstrated rapid, high-quality production of therapeutic monoclonal antibody targets, including a panel of rituximab biosimilar/biobetter molecules and antiviral antibodies against influenza and dengue fever.

[1]  Carola Engler,et al.  Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors , 2006, Proceedings of the National Academy of Sciences.

[2]  D. Montefiori,et al.  Rapid High-Level Production of Functional HIV Broadly Neutralizing Monoclonal Antibodies in Transient Plant Expression Systems , 2013, PloS one.

[3]  S. Marillonnet,et al.  Magnifection--a new platform for expressing recombinant vaccines in plants. , 2005, Vaccine.

[4]  G. A. Lazar,et al.  Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions , 2010, mAbs.

[5]  Pilar Giraldo,et al.  A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. , 2014, Blood cells, molecules & diseases.

[6]  B. Yassine-Diab,et al.  Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. , 2014, Clinical immunology.

[7]  J. Strong,et al.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™ , 2014, Nature.

[8]  J. Featherstone,et al.  Clinical Trial of a Plant-Derived Antibody on Recolonization of Mutans Streptococci , 2005, Caries Research.

[9]  R. Levy,et al.  Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study , 2008, Proceedings of the National Academy of Sciences.

[10]  R. Verrijk,et al.  Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[11]  제임스 스코트 크라우,et al.  Production of Antibodies , 1942, Nature.

[12]  S. Garger,et al.  Making an ally from an enemy: plant virology and the new agriculture. , 2002, Annual review of phytopathology.

[13]  R. Collins,et al.  Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma , 2015, BioMed research international.

[14]  K. Whaley,et al.  High‐level rapid production of full‐size monoclonal antibodies in plants by a single‐vector DNA replicon system , 2010, Biotechnology and bioengineering.

[15]  N. Natarajan,et al.  Immunogenicity in humans of an edible vaccine for hepatitis B. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  V. Yusibov,et al.  A novel two-component Tobacco mosaic virus-based vector system for high-level expression of multiple therapeutic proteins including a human monoclonal antibody in plants. , 2010, Virology.

[17]  S. Marillonnet,et al.  Systemic Agrobacterium tumefaciens–mediated transfection of viral replicons for efficient transient expression in plants , 2005, Nature Biotechnology.

[18]  Brian J. Ward,et al.  Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza , 2010, PloS one.

[19]  A. Laffan,et al.  Lactoferrin for the Prevention of Post-antibiotic Diarrhoea , 2011, Journal of health, population, and nutrition.

[20]  M. Schenerman,et al.  Advances in the assessment and control of the effector functions of therapeutic antibodies , 2011, Nature Reviews Drug Discovery.

[21]  Ernie Hiatt,et al.  Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. , 2010, Plant biotechnology journal.

[22]  M. Levine,et al.  Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. , 2000, The Journal of infectious diseases.

[23]  A. Hiatt,et al.  Production of antibodies in transgenic plants , 1989, Nature.

[24]  Nicotiana benthamiana: Its History and Future as a Model for Plant-Pathogen Interactions. , 2015, Molecular plant-microbe interactions : MPMI.

[25]  J. Katz,et al.  Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults. , 2014, Vaccine.

[26]  D. Elstein,et al.  Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease. , 2015, Blood cells, molecules & diseases.

[27]  H. Koprowski,et al.  Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. , 2002, Vaccine.

[28]  Andre Sharon,et al.  Automated Production of Plant-Based Vaccines and Pharmaceuticals , 2012, Journal of laboratory automation.

[29]  G. Lomonossoff,et al.  pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. , 2009, Plant biotechnology journal.

[30]  S. Marillonnet,et al.  Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.